A safety study of oncolytic virus HSV1716 in patients with mesothelioma

Phase 1

• Conditions: Malignant Pleural Mesothelioma; MedDRA version: 14.1Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2010-024496-37-GB
• Lead Sponsor: Virttu Biologics Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10-14
• Last Update Posted: 2 October 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1.Patients with histologically proven malignant pleural mesothelioma
2.Patients with disease which is not amenable to potentially curative resection
3.Patients with pleural effusions and/or ‘trapped lung’ who
(i)have an existing indwelling pleural catheter for draining of excess pleural fluid or
(ii)require the insertion of an indwelling pleural catheter to drain excess pleural fluid
4.Patients with a performance status = 2 (ECOG)
5.Age of at least 18 years (at screening)
6.Ability to give written informed consent as evidenced by signature on the patient consent form, to communicate well with the investigator and to comply with the expectations of the study

Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 6
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 6

Exclusion Criteria

1.Patients likely to require palliative radio- or chemotherapy within 30 days
2.Any evidence of uncontrolled cardiac or respiratory disease that would be a contra-indication for virus administration
3.Any other serious medical or psychiatric disorder that would be a contra-indication for virus administration
4.Acute active infection of any kind or other severe systemic disease or medical or surgical condition that is deemed significant by the principal investigator
5. Patients with immunosuppressive disorders or on systemic steroids > 5mg prednisolone/day
6.Pregnancy: women of childbearing potential not taking adequate contraception, and women who are breast feeding
7.Previous treatment with investigational viral therapy products
8.Administration of any unlicensed or investigational product within 8 weeks of entry to the study
9.No prior or concurrent malignancy within 5 years other than basal cell carcinoma of the skin or in situ neoplasia of the cervix uteri
10.Inadequate haematological function as defined by:
Haemoglobin (Hb)< 10g/dl
Neutrophil Count< 1.5 x 10^9/l
Platelets< 100 x 10^9/l
11.Deranged liver function tests: serum bilirubin = 1.5 x upper limit of normal reference range for laboratory; transaminases = 5 x upper limit of normal reference range
12.Patients with inadequate renal function: serum creatinine = 1.5 x upper limit of reference range for laboratory
13.Patients whose indwelling catheter is not of the type approved by the sponsor for use in the study
14.Outwith any of the inclusion criteria above or considered unsuitable for entry into the study in any other way at the discretion of the principal investigator

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified